JNJ Johnson & Johnson
Filed: 3 Dec 20, 4:47pm
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
December 3, 2020
Johnson & Johnson
(Exact name of registrant as specified in its charter)
|(State or Other Jurisdiction of Incorporation)||(Commission File Number)||(IRS Employer Identification No.)|
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
Registrant's telephone number, including area code:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock, Par Value $1.00||JNJ||New York Stock Exchange|
|0.250% Notes Due January 2022||JNJ22||New York Stock Exchange|
|0.650% Notes Due May 2024||JNJ24||New York Stock Exchange|
|5.50% Notes Due November 2024||JNJ24BP||New York Stock Exchange|
|1.150% Notes Due November 2028||JNJ28||New York Stock Exchange|
|1.650% Notes Due May 2035||JNJ35||New York Stock Exchange|
Item 5.02(d). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Johnson & Johnson (the "Company") announced on December 3, 2020, that Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General, has been appointed to its Board of Directors (the "Board"), effective immediately. Dr. West will serve as a member of the Board’s Science, Technology & Sustainability Committee, effective as of January 1, 2021. As a non-employee Director of the Company, Dr. West will receive compensation as described in the “Director Compensation” section of the Company's 2020 Proxy Statement.
The Company's press release announcing the appointment is attached to this Report as Exhibit 99.1.
Item 9.01. Exhibits
Exhibit No. Description of Exhibit
99.1 Johnson & Johnson Press Release dated December 3, 2020.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Johnson & Johnson|
|Date:||December 3, 2020||By:||/s/ Matthew Orlando|